and CDepartment ofPediatrics, Bridgeport Hospital Bridgeport, Connecticut Twenty-three patients were evaluated from 1-15 (mean 6) years after recovering from an episode of diarrhea-associated childhood hemolytic uremic syndrome (DA-HUS). All patients had received only conservative treatment; none had been given experimental, anti-coagulant, or immunological therapies. Follow-up studies included morphologic and duplex Doppler sonograms. Doppler sonography was used to determine the resistive index, a measure of renovascular resistance. Histories and physical examiniations revealed no abnormalities. Results of laboratory studies, which included calculated glomerular filtration rates, were all within normal limits, except for one patient with minor urinary abnormalities. Renal sonograms showed no significant abnormalities of kidney length or parenchymal appearance. However, Doppler sonographic examinations revealed that the DA-HUS patients demonstrated less of a decrease in renovascular resistance with age than did the control group (p<0.0002). After recovery, patients treated exclusively with conservative management during an acute episode of DA-HUS appeared to have an excellent long-term prognosis. Comparison of our results with those from other studies in which investigational therapies have been used during the acute phase of DA-HUS suggests that latent toxicities which cause long term sequelae may not have been appreciated previously. The clinical significance of the altered renal vascular resistance remains to be delineated.
INTRODUCTION
HUS' is defined by the acute onset of microangiopathic hemolytic anemia, thrombocytopenia, and renal dysfunction. DA-HUS is the most common form of the disease [1] . It usually follows a diarrheal prodrome and may be accompanied by central nervous system complications including seizures and coma [1, 2] . Over the past severl decades, the recognition and diagnosis as well as true incidence of DA-HUS has increased, and this entity is currently considered to be the most common cause of acute renal failure in infants and children in developed countries [1, 3, 4] . The short-term outcome is generally excellent and appears to be fairly consistent among various institutions despite the use of varying modes of therapy [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] . However, less is known about the long term prognosis for patients who appear to recover completely from the acute episode. d"o whom all correspondence should be addressed. Department of Pediatrics, Yale University School of Medicine, New Haven, CT 06520 "Abbreviations used: HUS, hemolytic uremic syndrome; DA-HUS, diarrhea-associated hemolytic uremic syndrome; US, ultrasound; YNNH, Yale New-Haven Hospital; BUN, blood urea nitrogen, RL resistive index, ESRD, end-stage renal disease; TMA, thrombotic microangiopathy.
I
This report describes the experience at Yale University School of Medicine where 23 children were treated for DA-HUS between 1974 and 1989. All patients studied had initally recovered spontaneously and completely from the acute episode of DA-HUS from 1-15 years previously and had received only conservative, supportive therapy. Renal duplex Doppler sonographic techniques, as well as standard laboratory and clinical measurements, allowed for a non-invasive assessment of renal status. Doppler sonograms were used to derive the resistive index (RI), a measure of renovascular resistance. The RIs of the study group were compared to those of a group of normal patients of similar ages. The goals of this study were a) to define the long term outcome for children who were treated conservatively for DA-HUS, and who appeared to have a complete recovery from the initial acute episode, b) to evaluate long-term complications which occur in this group of patients who were treated conservatively relative to other patients who received investigational therapies, and c) to determine if any residual changes in renal blood flow were present in these patients. METHODS This study was approved by the Human Investigations Committee of Yale University School of Medicine.
Patients. Computerized listings of the discharge diagnoses from the Pediatric Services of Yale-New Haven Hospital, the Hospital of St. Raphael (New Haven, CT), and Bridgeport Hospital (Bridgeport, CT) between January 1, 1974 and December 31, 1989 , were reviewed to determine those patients with a diagnosis of hemolytic uremic syndrome. The following data were recorded from the medical records of these patients: demographic information and presenting symptoms; laboratory data on admission BUN, serum creatinine, hemoglobin, hematocrit, platelet count, and serum sodium, potassium bicarbonate, and chloride, and blood pressure on admission; maximum BUN, creatinine, and blood pressure values during the hospital stay; minimum hemoglobin, hematocrit, and platelet levels during hospitalization; the most abnormal urinalysis obtained during admission; the advent of oliguria (urine ouput < 0.5 ml/kg/hr), length of oliguria, the need for dialysis, and length of dialysis, if performed; the need for transfusions and the type and amount of transfusions, if given; the occurrence of seizures, complications during the hospital stay, outcome, and length of hospital stay; and the results of the most recent follow-up evaluation available including blood pressure, urinalysis, BUN, serum creatinine, hemoglobin, hematocrit, platelet count, height, weight, and length of follow-up. Patients who met the following criteria were eligible for this study: 1) Patients were less than 18 yr of age when diagnosed with hemolytic uremic syndrome, defimed by the triad of microangiopathic hemolytic anemia (hematocrit < 30% and schistocytes on peripheral smear), thrombocytopenia (platelet count < 150,000/mm3), and renal dysfunction (BUN > 18 mg/dl and a serum creatinine concentration > 1.2 mg/dl). 2) No evidence of recurrent or familial pattern of HUS. 3) Treatment with conservative, supportive management only, incuding dialysis and blood transfusions as necessary, but not with antithrombotic, antiplatelet, or fibrinolytic agents or with fresh frozen plasma, intravenous immunoglobulin, or plasmapheresis. 4) Apparent complete recovery from the acute illness as determined by hematocrit, platelet count, urine output, BUN, serum creatinine, and blood pressure. 5) Follow-up of one year or more after recovery from the acute episode.
Follow-up evalution. Subjects or their parents were mailed consent forms and letters explaining the project and were then contacted by telephone and asked to come to YNHH for follow-up studies. Follow-up evaluation included a medical history, physical examination, two blood pressure measurements always taken separately by the same two exam-iners (J. O'B., S.V.W.) and measurements of height and weight. Blood was drawn and sent to the YNHH clinical laboratories for measurement of hemoglobin, hematocrit, platelet count, BUN, and serum creatinine concentrations. Analysis of fresh urine was performed using a dipstick (Labstix) to detect protein, glucose, ketones, or occult blood, and with examination of microscopic urine sediment by the same two observers (J. O Sonographic examinations of renal morphology included determinations of kidney size, the presence or absence or renal scarring, abnormalities in the collecting system, such as calyceal or renal pelvic dilatation, and cortical-medullary differentiation. Kidney length was plotted against age, weight, height, and body surface area and compared to values for normal children [21] . Lengths above the 95th or below the 5th percentiles were considered abnormal. Doppler sonographic studies included determination of the resistive index at the level of the segmental renal arteries and examination for the presence of a patent main renal vein. The RI or Pourcelot index is defined as:
[peak systolic velocity -end diastolic velocity] peak systolic velocity
The RI represents a quantitative assessment of the blood flow pattern through the vasculature and provides an assessment of renovascular resistance [22] . With increased resistance to flow, the RI increases because the wave form is more steep with increased systolic velocity and decreased diastolic velocity. This formula has been shown by Patriquin et al. to predict the severity of renal microangiopathy, vascular resistance, and the resolution of oliguria and anuria during the acute phase of hemolytic uremic syndrome [23] .
These values were compared with those of a randomly chosen control group of 30 children (60 kidneys) of similar ages to the study subjects with no known renal or cardiac disease. Statistical analysis. The acute phase variables of the subjects in the study group and of the patients lost to follow-up were compared using the Chi-square test with the Yates continuity correction, Fisher's exact test, or the two-tailed Student t-test, as appropriate, with a p value of < .05 considered significant. Comparison of the resistive indices of the DA-HUS group with those of the control group was done using a z-test. Relationships between continous variables were determined using the Pearson product-moment correla-tion coefficient, linear regression analysis, the general linear model to determine P for each slope, and analysis of covariance. In all cases, p < .05 was considered significant. RESULTS Patient data. Forty-seven patients were initally identified as having been admitted with HUS to one of the three hospitals between January 1, 1974 and December 31, 1989. Overall, six (12.8%) of the 47 HUS patients never recovered normal renal function: four (8.5%) developed end-stage renal disease (ESRD) and two (4.3%) died during the acute phase. Of these six patients with poor acute outcome, three did not experience a diarrheal prodrome.
There were 41 patients with spontaneous recovery from the acute episode. One of these patients had experienced an episode of HUS associated with total body irradiation received in preparation for a bone marrow transplant and was not included in this study.
One patient had a recurrence 15 mo after the initial episode. Of the remaining 39 patients with DA-HUS, 10 could not be located, but all had spontaneously recovered normal renal function by the time of discharge and maintained normal renal function for as long as they were followed (median follow-up period 1 mo., range 0 to 22 mo.). Twenty-three of the remaining 29 patients with DA-HUS agreed to participate in this study. The six patients who declined to participate were in good health with no known deterioration of renal function 1 to 16 yr. (median 4 yr.) after discharge.
Comparison of acute phase features of the patients in the study group with those of the sixteen patients lost to follow-up (10 not found and 6 refused to participate) revealed the following significant differences: oliguria was more frequent in the study group (68% vs 24%; p <0.02), and peritoneal dialysis was required more often in the study group (55.5% vs 18%; p < .05). These differences suggest that the subjects in the study group may have actually experienced more severe episodes of HUS than did those lost to follow-up.
There were 15 females and 8 males in the final study group. All subjects were
Caucasian, all had experienced DA-HUS and the mean age of admission to the hospital during the acute illness was 4. acute episode of DA-HUS. All patients were at or above the 10th percentile for height and weight for their age and sex. All patients (from whom previous height and weight data were available) had maintained their appropriate growth curves. No systolic or diastolic blood pressures were above the 80th percentile for age and sex. All patients had normal physical examinations including fundoscopic, heart, lung, abdominal, extremity, and neurologic examinations.
All hematological data were normal except for 3 hematocrit values within 1% of the lower limit of normal. Urinalysis and renal function studies were normal in 22 of 23 patients (Table 1) : mean serum creatinine concentration was 0.6 ± 0.2 mg/dl (range 0.4 -1.1 mg/dl); BUN, 15 ± 5 mg/dl (range 6 -32 mg/dl); and creatinine clearance, (128.0 + 23.5 ml/min/1.73m2). One patient (#21) had an abnormal urinalysis (1+ protein and a single granular cast), an elevated urine protein: creatinine ratio of 0.53 (normal < .20), and a BUN of 32 mg/dl. Her calculated GFR was 98.8 mL/min/1.73m2.
Ultrasound Data ( Table 2 ). Evaluation of 40 kidneys from 20 subjects (patients #15, #16, and #23 were not available to study) using renal sonography to measure longitudinal kidney length showed no kidneys to be smaller than the 5th percentiles for age, height, or weight. The length of the left kidney of subject #10 was at the 95th percentile for weight only. The length of the left kidney of patient #12 was greater than the 95th percentile for height only. The length of the right kidney of patient #17 was greater than the 95th percentile for age, height, and weight. In each case (#10, #12, #17), the contralateral kidney was within 1 cm of the larger kidney; thus, the increased size of the larger kidney was not Figure 1 ). However, using covariance analysis, the DA-HUS patients demonstrated less of a decrease in RI with age than did the control group (p < .0002). Thus, for the DA-HUS patients, RI values overall were higher than expected for a given age. The RIs of these patients were not studied longitudinally, the patients had their acute illness at different ages and have had various lengths of followup. Therefore, it is difficult to determine for certain the trend of individual RIs over time and whether the rate of RI decrease slowed, stopped falling completely, or even began to rise after the initial episode of DA-HUS. However, in the DA-HUS patients, age correlated with length of time since hospitalization (r2 = .78, p < .0001). Furthermore, when RI was compared to length of follow-up, RI was found to fall slightly but significantly as length of time since the acute illness increased (r2 = .248, p = .0011; Figure 2 ). Taken together, these data suggest that renal vascular resistance in this group of children who recovered from DA-HUS was decreasing over time as it does in normal children, although at a significantly slower rate than was observed in the control group. (Table 3) . Overall, acute mortality has improved dramatically over the past 20 yr. This has been attributed, in part, to increasing recognition of milder cases of HUS as well as to improved supportive management. Gianantonio, who has reported the largest number of HUS patients, noted that over 15 years the acute mortality rate dropped from 47% to 6.25% with increasing use of peritoneal dialysis [2] . The question of whether or not to pursue more aggressive therapy has been controversial.
Damage to endothelial cells caused by an E.coli 0157:H7 Vero cell cytotoxin (VT1 or SLT-I) is currently considered the primary pathogenic mechanism of classic HUS [1, [30] [31] [32] [33] . The fibrin depositions associated with TMA have led investigators to suggest additional mechanisms including activation of intravascular coagulation cascade, platelet activation, and prostacyclin deficiency [2, 34, 35] . Therefore, therapeutic interventions with anti-thrombotic agents such as anti-coagulants, platelet inhibiting agents, and fibrinolytic agents to minimize the extent and effects of TMA have been tried [6, 27, 36, 37] . There have also been trials of plasmapheresis and infusions of fresh frozen plasma, prostacyclin, and immunoglobulin attempting to correct the proposed deficiencies in prostacyclin synthesis and other abnormal factors found in the sera of HUS patients [14, 15, [38] [39] [40] . None of these therapies has been shown to improve definitively or signiflcantly the acute outcome of DA-HUS. Janssen et al.
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Siegler et al. Overall mortality (4.3%) and morbidity (8.5% ESRD) rates for the present series during the acute stage of the illness are comparable to those previously reported (Table  3) . The mortality and morbidity of the present series of patients with DA-HUS who were managed conservatively are compatible with other series which include experimental therapeutic interventions. Moreover, since an entry criterion of this study was an apparent spontaneous resolution of the acute episode of DA-HUS, it is important to note that follow-up data are not biased by high acute morbidity or mortality.
Published observations of long term follow-up status of children with HUS are highly variable (Tables 3 and 4) . Over the past 20 yr., long-term follow-up studies have shown the proportion of patients without any sequelae to range from 60-97% (excluding the particularly severe cases reported from Argentina). Proportions of patients with residual hypertension (0-20%), proteinuria (0-32%), low creatinine clearances (0-57%), and chronic renal failure (0-11%) have also been inconsistent. Interpretation of these large variations in outcome is difficult. Most long-term follow-up studies describe collectively all HUS patients, some or all of whom were often acutely treated with multiple and differing therapeutic approaches and some of whom did not have a diarrheal prodrome. Occasionally, there is no mention of how patients were treated during the acute episode. The putative effects of experimental therapies, administered during the acute episode, on long-term outcome are not known. Various experimental interventions could have had significant effects on later outcome that were not, initially, appreciated or anticipated. Many long-term follow-up studies also do not distinguish a recovery group from those who never regained renal function when reporting rates of long term sequelae.
Another issue confounding the data on later sequelae of childhood HUS is the difficulty of detecting early renal insufficiency non-invasively. Standard measurements of renal function (serum creatinine and BUN) may not become detectably abnormal until renal failure is fairly advanced. ORegan et al. found no correlation between abnormal GFR measured by 9*,TcDTPA plasma slope clearance and normal BUN and plasma creatinine concentrations in follow-up of patients with HUS [41] which raises the possibility that some post-HUS patients with residual chronic renal insufficiency are being missed.
This follow-up study of HUS patients differs from many previous similar studies in that all subjects had DA-HUS and were treated conservatively during the acute illness. Thus, the problem of various, confounding acute therapies which might complicate the natural history of recovery from HUS is eliminated. Also, this follow-up study focussed exclusively on those patients who recovered completely from the initial episode. Finally, in addition to routine follow-up testing, this study incorporated measurements of creatinine clearance as well as sonographically determined kidney size, appearance, and renovascular resistance as indications of residual renal injury.
Comparison of features during the acute phase indicated that those lost to follow-up (16 of 39 eligible patients) may have experienced a less severe course than did those in the study. This suggested that the observed outcomes in the study group were not biased because of a mild initial phase of HUS. Thus, it seems unlikely that the parameters examined underestimated the rates of later sequelae for the entire group.
Calculated GFRs which are based on serum creatinine concentrations may overestimated true renal function [41, 42] . Thus, subtle decreases in GFR may have been undetected. However, the outcome measures used in this study were those most commonly available, and the estimation of GFR by the Schwartz formula has been shown to correlate closely with inulin clearance [19] . If substantial declines in GFR were present, one would have anticipated that abnormalities in kidney size, composition, or shape would also have been present and these latter alterations were not detected.
By routine criteria, including GFR calculations, none of the patients in this study demonstrated any significant sequelae, thus appearing to exhibit more favorable outcomes than have patients reported elsewhere [2, 11, 13, 16, 17] . One patient had minor urine abnormalities noted on one examination. Furthermore, all kidneys measured were of normal size, and no evidence of renal parenchymal scarring was seen by sonographic evaluation. These results are most similar to those reported by Janssen [29] , Kaplan [5] , and Dolislager [8] , who described a combined total of 92 HUS patients from Belgium, South Africa, and California, respectively. All of these patients were treated conservatively during the acute episode, and in each group 90% were without any sequelae at follow-up.
Other follow-up series have shown less successful outcomes (Table 4) . Of note, the poorer outcome has been reported more frequently in studies in which experimental therapy was used during the acute episode or therapeutic intervention is not delineated. While it could be argued that more severely ill patients are selected for experimental therapies, the acute phase variables assessed in this study suggest that the incidence of oliguria, dialysis therapy, or seizures in our group of patients were similar to those reported by others. Thus, the poorer outcome reported in other studies is not necessarily from inclusion of patients who were more acutely ill compared to those reported in this study. Alternatively, it is possible that higher rates of sequelae seen in other studies resulted from latent side effects of various investigational therapies used during the acute episode. For example, Binda Ki Muaka et al. initially found complete recovery in 38 of 39 patients who had been treated with heparin and dipyridamole during the acute episode [10] . However, a reevaluation of this same group of patients, by Van Dyck et al., found only 70% normal at 10 yr. follow-up [16] . Similarly, in a 5 -21 yr. follow-up of 103 children with DA-HUS, Fitzpatrick et al. reported that 31% had microalbuminuria, 18% had reduced GFR, and 10% had both in association with higher systolic blood pressure [11] . Unfortunately, therapeutic interventions, during the acute phase of the illness, are not delineated in this latter study [11] . While our findings are not definitive, an intense and thorough evaluation of this possibility should be undertaken in those centers which have employed investigational therapies.
The only abnormality found among the patients in the present series was a significantly slower age-related decrease in renovascular resistance determined by Doppler ultrasound examination of the segmental renal arteries. This statistically significant difference in resistive index between DA-HUS and normal subjects did not appear to represent a clinically relevant difference, at least for up to 15 yr. after the acute episode. The increase in renal vascular resistance and diminished rate of decline in RI in HUS patients may reflect the irreversible injury to some glomeruli or microvascular beds during the acute episode. Whether or not the DA-HUS patients will eventually achieve normal RI values is unclear from the present data. Longer follow-up would be necessary to determine whether the RIs of these DA-HUS patients continue to fall until they reach normal levels, or whether after a certain age renal vascular resistance will plateau at a higher level and represent a harbinger of later sequelae, possibly in adulthood. This possibility would be compatible both with the poorer outcome reported by Fitzpatrick [11] , whose patients were studied later in follow-up than ours, and with the observation by Siegler et al. that abnormalities appeared in some cases after an interval of apparent recovery [171.
In conclusion, this study indicates that patients who have recovered from DA-HUS with only conservative management have an excellent prognosis and provides supportive evidence for the efficacy and safety of conservative management of the acute phase of DA-HUS. However, the clinical implications of increased renovascular resistance, without other clinical sequelae, remain to be determined. ACKNOWLEDGEMENT Raphael, New Haven, CT), to Dr. James F. Jekel (Yale University School ofMedicine) for assistance
